Stocklytics Platform
Asset logo for symbol NVAX
Novavax
NVAX56
$12.96arrow_drop_down4.77%-$0.65
Asset logo for symbol NVAX
NVAX56

$12.96

arrow_drop_down4.77%

Income Statement (NVAX)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT$162.11M-$138.73M-$183.56M-$128.61M$60.98M
EBITDA$173.24M-$126.58M-$172.77M-$117.29M$71.05M
gross Profit$379.44M$45.04M$142.46M-$76.86M$368.64M
NET Income$162.38M-$147.55M-$178.38M-$130.77M$58.00M
total Revenue$415.48M$93.85M$291.34M$22.06M$424.42M

Balance Sheet (NVAX)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$457.40M-$261.70M-$298.29M-$428.99M-$306.96M
stockholders Equity-$431.70M-$867.08M-$716.92M-$678.35M-$754.51M
total Assets$1.81B$1.35B$1.85B$1.65B$1.68B
total Debt$233.24M$229.33M$280.63M$222.11M$198.94M
total Liabilities$2.25B$2.22B$2.57B$2.33B$2.43B

Cash Flow (NVAX)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$258.21M$5.88M$100.38M$197.12M$61.33M
free Cash Flow$311.14M-$90.80M-$185.85M-$58.04M-$179.71M
investing Cash Flow----$18.39M-$7.77M
operating Cash Flow$314.26M-$83.55M-$176.78M-$39.65M-$171.93M

Novavax (NVAX) Financials

Novavax Inc (NVAX) is a biotechnology company that specializes in the development of innovative vaccines to prevent infectious diseases. The company's financials provide valuable insights into its performance, profitability, and financial standing. The income statement shows Novavax's revenue and expenses, ultimately leading to its net income. The company's ebit (earnings before interest and taxes) and ebitda (earnings before interest, taxes, depreciation, and amortization) indicate its operating profitability and ability to generate cash flow from operations. Novavax's gross profit reflects the difference between its revenue and cost of goods sold, highlighting its manufacturing efficiency. The net income from stockholders represents the portion of profit attributable to shareholders after accounting for all expenses and taxes. Novavax's total revenue encompasses all sources of income, including product sales, collaborations, and grants.
Novavax's balance sheet provides a snapshot of the company's financial position at a specific point in time. It shows the value of Novavax's assets, including cash equivalents, investments, and property, plant, and equipment. The net debt represents the company's total debt minus its cash and cash equivalents, providing an indicator of its overall debt burden. Stockholders' equity represents the value of the company attributable to its shareholders, calculated by subtracting total liabilities from total assets. Novavax's total assets encompass all tangible and intangible resources it owns, while total debt includes both short-term and long-term liabilities. The cash flow statement illustrates how cash is generated and used by Novavax. It includes operating cash flow, which measures cash generated from core business operations, and investing cash flow, which reflects cash used for investments such as acquisitions or capital expenditures. Financing cash flow indicates cash flows from activities such as issuing or repurchasing stock and paying dividends. Lastly, free cash flow is the cash remaining after deducting capital expenditures from operating cash flow, representing the amount available for strategic investments or debt reduction.
In conclusion, Novavax Inc's financials provide a comprehensive overview of its financial performance and position. These metrics assist investors and stakeholders in assessing the company's profitability, operational efficiency, and ability to meet financial obligations. By analyzing Novavax's income statement, balance sheet, cash flow statement, and other relevant financial information, interested parties can make informed decisions regarding their investment in the company.
add Novavax  to watchlist

Keep an eye on Novavax

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media